(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 October 2025 (09.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/210275 A1

(51) International Patent Classification:
A61K 38/16 (2006.01) *C07K 14/31* (2006.01)
C07K 14/16 (2006.01) *C07K 14/315* (2006.01)

(21) International Application Number:
PCT/EP2025/059377

(22) International Filing Date:
04 April 2025 (04.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24168804.3 05 April 2024 (05.04.2024) EP

(71) Applicants: **BLUE BEES THERAPEUTICS** [FR/FR]; Pépinière d'Entreprises Wipse Parc, Club Orsay Université, 21 Rue Jean Rostand, 91400 ORSAY (FR). **COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES** [FR/FR]; 25 rue Leblanc, Bat le Ponant, 75015 PARIS (FR).

(72) Inventors: **LEONETTI, Michel**; c/o BLUE BEES THERAPEUTICS, Pépinière d'Entreprises Wipse Parc, Club Orsay Université, 21 Rue Jean Rostand, 91400 ORSAY (FR). **DELUCE, Nora**; c/o BLUE BEES THERAPEUTICS, Pépinière d'Entreprises Wipse Parc, Club Orsay Université, 21 Rue Jean Rostand, 91400 ORSAY (FR).

(74) Agent: **CASALONGA**; 31 Rue de Fleurus, 75006 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with amended claims (Art. 19(1))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: IMMUNOMODULATORY COMPLEX COMPRISING HEPARAN SULFATE BINDING PEPTIDE AND USES THEREOF FOR THERAPY

(57) Abstract: The invention concerns an immunomodulatory complex comprising a Tat polypeptide of SEQ ID NO: 1 or a variant thereof which binds heparan sulfate, linked to a ligand of an antigen-presenting cell, NK or NKT cell surface receptor other than a sulfated sugar of the glycosaminoglycan family, with the proviso that the immunomodulatory complex lacks the peptide Tat 49-57 (RKKRRQRRR), and its use in immunotherapy of cancer, infectious, immunoinflammatory or autoimmune diseases.

WO 2025/210275 A1